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Background: To establish a model of pancreatic cancer induced by 7,12-dimethylbenzantracene (DMBA) in
Sprague–Dawley (SD) rats, and detect the expression of DNA-repair proteins (MGMT, ERCC1, hMSH2, and hMLH1)
and their significance in pancreatic cancer and non-cancerous pancreatic tissues of SD rats.
Methods: DMBA was directly implanted into the parenchyma of rat pancreas (group A and group B), and group B
rats were then treated with trichostatin A (TSA). The rats in both groups were executed within 3 to 5 months, and their
pancreatic tissues were observed by macrography and under microscopy. Meanwhile, the rats in the control group
(group C) were executed at 5 months. Immunohistochemistry was used to assay the expression of MGMT, ERCC1,
hMSH2, and hMLH1.
Results: The incidence of pancreatic cancer in group A within 3 to 5 months was 48.7% (18/37), including 1 case of
fibrosarcoma. The incidence of pancreatic cancer in group B was 33.3% (12/36), including 1 case of fibrosarcoma. The
mean of maximal diameters of tumors in group A was higher than that in group B (P <0.05). No pathological changes
were found in pancreas of group C and other main organs (except pancreas) of group A and group B. No statistical
differences were found among the positive rates of MGMT, ERCC1, hMSH2, and hMLH1 in ductal adenocarcinoma and
non-cancerous pancreatic tissues of group A (P >0.05). The positive rates of MGMT, ERCC1, hMSH2, and hMLH1 were
significantly lower in ductal adenocarcinoma than those in non-cancerous tissues of group B (P ≤0.05). All pancreas of
group C had positive expression of MGMT, ERCC1, hMSH2, and hMLH1 and two cases of fibrosarcoma showed a
negative expression.
Conclusions: DMBA, directly implanted into the parenchyma of pancreas, creates an ideal pancreatic cancer model
within a short time. TSA might restrain DNA damage related to the genesis and growth of pancreatic cancer in rats.
The DNA-repair proteins, including MGMT, ERCC1, hMSH2, and hMLH1, might play an important role in the genesis of
pancreatic cancer induced by DMBA in rats.
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Table 1 Incidences of pancreatic tumors in groups A and B
(case number ratio (%))
Group n 3rd month 4th month 5th month Total cases
A 37 2/7 (28.6) 4/10 (40.0) 12/20 (60.0) 18/37 (48.7)
B 36 1/6 (16.7) 3/10 (30.0) 8/20 (40.0) 12/36 (33.3)
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Pancreatic cancer is a solid malignancy characterized by
its rapid growth and propensity to invade adjacent or-
gans and metastasize. Worldwide, pancreatic cancer
causes approximately 213,000 deaths each year. The 1-
year survival rate is around 20% and 5-year survival rate
is less than 5% in spite of aggressive therapies [1].
Within the last two decades, research has shown that
pancreatic cancer is fundamentally a genetic disease
caused by inherited germline and acquired somatic mu-
tations in cancer-associated genes, and more and more
investigation of molecular pathogenesis has been used in
the diagnosis and treatment of pancreatic cancer. To
build useful models studying the pathological molecular
mechanisms of pancreatic cancer, Rivera et al. directly
implanted dimethylbenzanthracene (DMBA) into the
parenchyma of the rat pancreas and found a pancreatic
cancer incidence of 39% within 10 months [2]; Bockman
et al. reported similar studies [3].
Trichostatin A (TSA) is a histone deacetylase inhibitor
with a broad spectrum of epigenetic activities. It can up-
regulate the expression of several genes and restrain
other genes’ expression, thus intervening in the genesis
and development of tumors. In vivo or in vitro experi-
ments have confirmed that TSA could restrain the gen-
esis of some tumors and control tumor progression by
restraining tumor angiogenesis and changing the tumor
microenvironment [4]. Some studies have shown that
TSA acts as a tumor suppressor in human pancreatic
cancer cell lines [5,6].
The DNA mismatch repair (MMR) system is an inbuilt
security system that can repair DNA mismatch in hu-
man cells, and plays an important role in retaining the
integrality and stability of genes. The main MMR genes
are hMSH1-6, hMLH1-5 and others, and the methylation
of MMR genes and/or the loss of expression of their
proteins plays an important role in malignant tumorigen-
esis [7-11]. O6-methylguanine DNA methyltransferases
(MGMT) is a high-performance DNA-repair enzyme,
which can protect cells from alkylating agent damage and
prevent cell carcinogenesis [11-16]. Excision repair cross-
complementing gene 1 (ERCC1) is a member of the exo-
nuclease repair enzyme family, and its low expression is
always related with elevated cancer incidence while its
high expression is always related with resistance to plat-
inum drugs [17-21].
Since no studies have examined the expression levels of
DNA-repair proteins (MGMT, ERCC1, hMSH2, and
hMLH1) in pancreatic cancer induced by DMBA and non-
cancerous pancreatic cancer tissues in rats, little is known
about the effects of MGMT, ERCC1, hMSH2, and hMLH1
on rat pancreatic cancer induced by DMBA. In this study,
DMBA was directly implanted into the parenchyma of the
pancreas of rats to establish a pancreatic cancer model,and TSA injection was given to establish the intervention
group. The expression levels of MGMT, ERCC1, hMSH2,
and hMLH1 in pancreatic cancer and non-cancerous pan-
creatic tissues was detected and their effect on the process
of inducing cancer by DMBA was assessed.
Methods
Animal model
Ninety Sprague–Dawley (SD) rats (no sex limit), weigh-
ing between 150 and 200 g were used. These rats were
randomly divided into three groups: 40 in the pancreatic
cancer model group (group A), 40 in the TSA intervention
group (group B), and 10 in the control group (group C).
The rats were treated with preoperative fasting for 24
hours (no water ban), and 2% amyl-barbital was injected
into the abdomen under anesthesia. The rats’ abdomens
and parenchyma were then dissected (1 mm) and DMBA
(9 mg) was directly implanted into the parenchyma of the
pancreas in groups A and B, followed by suturing. The
rats were raised in common conditions after operation,
and rats in group B were injected with 1 mL TSA (1 μg/
mL) weekly through the abdomen. Except for natural
death, the rats were executed randomly in the third month
(7 rats in group A and 6 rats in group B), in the fourth
month (10 rats in both groups A and B), and in the fifth
month (20 rats in both groups A and B) after operation.
Rats in group C, which were treated without DMBA im-
plantation and treated in the same condition as group A,
were executed in the fifth month after operation.
The design of this study was approved by the medical
ethics commitee of the Second Hospital of Yueyang City.
Macrography and pathological observation
The livers, gallbladder, stomach, intestine, and lung of
rats in groups A and B were observed by macrography.
After which the whole pancreatic tissues and some tis-
sues from the liver, gallbladder, stomach, intestines, and
lungs of rats were put into 4% formaldehyde for 16 to 18
hours. Conventional paraffin-embedded sections were
made with these specimens. Finally the sections were
dyed by hematoxylin and eosin staining, and observed
under microscopy.
Immunohistochemical staining of EnVision™
Immunostaining was conducted by use of the ready-to-
use, peroxidase-based EnVision™ Detection kit (Dako La-
boratories, CA, USA) according to the user manual.
Table 2 Pathological types of pancreatic tumors in groups










A 18 1 6 7 4
B 12 1 6 4 1
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paraffin-embedded tissues.
Rabbit anti-rat MGMT, ERCC1, hMSH2, and hMLH1
monoclonal antibodies were obtained from Cell Signal-
ing Technology, Inc. (Danvers, MA, USA). EnVision™
detection kit was from Dako Laboratories, CA, USA.
Cytoplasm and (or) cell nuclei containing brown-yellow
granules were defined as positive cells. The percentage
of positive cells was calculated from 10 random fields.
Cases with ≥25% positive cells were considered positive
and cases were otherwise considered negative [22,23].
The positive controls were the positive pancreatic cancer
biopsies provided by CST (Cell Signaling Technology,
Inc.) while the negative controls were prepared by 5%
fetal bovine serum substituting the primary antibody.
Statistical analysis
Data was analyzed by using the statistical package for the
Social Sciences Version 13.0 (SPSS 13.0). All the data were
analyzed by using χ2 test, rank-sum test, and Fisher’s exact
test.Figure 1 Pathological observation of rat pancreatic lesions induced b
(A) Poorly-differentiated ductal adenocarcinoma (group A); (B) Well-differen
(D) Severe atypical hyperplasia in ductal epithelia (group A).Results
Macrography
The incidence of pancreatic tumors in groups A and B
are shown in Table 1; the incidence of tumors in group
A was higher than that in group B (P >0.05). Both
groups A and B had one case of fibrosarcoma that devel-
oped liver metastasis and epiploon metastasis. The dis-
tribution of diameter of tumor mass in group A was
0.5–1.0 cm (7 cases), 1.0–2.0 cm (10 cases), and >2.0 cm
(1 case); and the distribution of diameter of tumor mass
in group B was 0.5–1.0 cm (9 cases), 1.0–2.0 cm (2
cases), and >2.0 cm (1 case). The mean of maximal
diameter of tumors in group A was higher than that in
group B (P <0.05). No pathological changes were found
by macrography in pancreas of group C and other main
organs (except pancreas) of groups A and B.
Pathological observation
Pathological results of pancreatic tumors in groups A
and B are shown in Table 2 and Figure 1A. Both non-
cancerous pancreatic tissues and peritumoral pancreatic
tissues in groups A and B showed hyperplasia to
atypical-hyperplasia. Non-cancerous pancreatic tissues
in group A which showed mild atypical-hyperplasia were
found in 5 cases (26.3%) and moderately to severely
atypical-hyperplasia in 10 cases (52.6%). The same tis-
sues were found in group B in 10 cases (41.6%) and 8
cases (33.3%), respectively; therefore, no statistical differ-
ences were found in the two groups (P >0.05). No patho-
logical changes were found by microscopy in pancreas ofy DMBA. Hematoxylin-eosin stain, original magnification × 200.
tiated ductal adenocarcinoma (group B); (C) Fibrosarcoma (group B);
Figure 2 DNA repair proteins expression in the ductal carcinoma of rat pancreas. EnVision immunohistochemistry, original magnification × 200
and positive reaction was mainly localized in the cytoplasm and/or nucleus. (A) MGMT positive expression in well-differentiated adenocarcinoma;
(B) ERCC1 positive expression in moderately-differentiated adenocarcinoma; (C) hMSH2 positive expression in moderately-differentiated adenocarcinoma;
(D) hMLH1 positive expression in well-differentiated adenocarcinoma.
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groups A and B.Table 3 Expression of MGMT, ERCC1, hMSH2, and hMLH1
in ductal adenocarcinoma and non-cancerous pancreatic
tissues (%)
Group n MGMT ERCC1 hMSH2 hMLH1
Pancreatic ductal
adenocarcinoma
A + B 28 15 (53.6) 13 (46.2) 14 (50.0) 12 (42.9)
A 17 9 (52.9) 8 (47.1) 9 (52.9) 8 (47.1)
B 11 6 (54.6) 5 (45.5) 5 (45.5) 4 (36.4)
Non-cancerous
pancreatic tissues
A + B 43 35 (81.4) 33 (76.7) 32 (74.4) 30 (70.0)
A 19 14 (73.7) 14 (73.7) 12 (63.2) 11 (57.9)
B 24 21 (87.5) 19 (79.2) 19 (79.2) 19 (79.2)
Pancreatic ductal adenocarcinoma compared with non-cancerous pancreatic
tissues in group A + B: χ2 MGMT = 6.30, P <0.05; χ
2
ERCC1 = 6.83, P <0.01; χ
2
hMSH2 =
4.43, P <0.05; χ2 hMLH1 = 5.08, P <0.05.
Pancreatic ductal adenocarcinoma compared with non-cancerous pancreatic
tissues in group A: PMGMT = 0.157, PERCC1 = 0.088, PhMSH2 = 0.103, PhMLH1 = 0.452.
Pancreatic ductal adenocarcinoma compared with non-cancerous pancreatic
tissues in group B: PMGMT = 0.042, PERCC1 = 0.050, PhMSH2 = 0.050, PhMLH1 = 0.018.Expression of MGMT, ERCC1, hMSH2, and hMLH1 in
pancreatic ductal adenocarcinoma and non-cancerous
pancreatic tissues
The positive rates of MGMT, ERCC1, hMSH2, and
hMLH1 (Figure 2) were significantly lower in ductal
adenocarcinoma than those in non-cancerous pancreatic
tissues in group A + group B (P <0.01 or P <0.05). No
statistical differences were found among the positive
rates of MGMT, ERCC1, hMSH2, and hMLH1 in ductal
adenocarcinoma and non-cancerous pancreatic tissues
of group A (P >0.05). The positive rates of MGMT,
ERCC1, hMSH2, and hMLH1 were significantly lower in
ductal adenocarcinoma than those in non-cancerous tis-
sues of group B (P <0.05). The ductal epithelium of non-
cancerous pancreas which had negative expression of
MGMT, ERCC1, hMSH2, and hMLH1 in groups A and B
all showed moderately or severe atypical-hyperplasia.
The fibrosarcoma had negative expression of MGMT,
ERCC1, hMSH2, and hMLH1, while pancreas of group C
had positive expression of MGMT, ERCC1, hMSH2, and
hMLH1 (Table 3). Expression of MGMT, ERCC1, hMSH2,
and hMLH1 had no obvious correlation with the size of
tumor mass and differentiation degree of ductal adenocar-
cinoma (P >0.05).Discussion
Establishing of a pancreatic cancer model can be
achieved through three kinds of methods [24-27]: 1) ex-
posing canine animal to carcinogen, 2) activating the on-
cogenes of transgenic mice, and 3) transplanting the
xenogenic pancreatic cancer tissues to athymic mouse.
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chyma of rat pancreas to establish a pancreatic cancer
model of rats and the incidence of cancer of SD rats
within 10 months was 39% [2]. Since then, a series of
mouse and rat pancreatic cancer models using DMBA
have been established [28-32]. TSA can increase intra-
cellular histone levels and up-regulate the expression of
several genes. Some experiments have confirmed that
TSA can restrain the genesis of some tumors by
restraining angiogenesis, inhibiting proliferative activity,
and promoting apoptosis of tumor cells [33-37]. After
we directly implanted a major dose of DMBA (9 mg)
into the pancreas parenchyma of SD rats, the incidence
of cancer in group A within 3 to 5 months was 48.7%,
and that in group B was 33.3%; their pathological types
were the same as those of human pancreatic ductal
adenocarcinoma, except for two cases of fibrosarcoma.
The incidence of cancer in group A was higher than that
in group B, but the difference had no statistical sig-
nificance (P >0.05). The mean of maximal diameter of
tumors in group A was higher than that in group B
(P <0.05). Our SD rat model of pancreatic cancer had
some merits: 1) the period of tumor formation was short
and the incidence of cancer was high; 2) the pathological
type was mainly the same as human pancreatic ductal
adenocarcinoma; 3) no pathological changes were found
in main organs (except pancreas); 4) the inhibitive effect
on carcinogenesis and growth of TSA was obvious; and
5) the cost was low.
MGMT is a high-performance DNA-repair enzyme
that can protect cells from alkylating agent damage and
can prevent cell carcinogenesis and death. The MGMT
gene is located in 10q26 and encodes 207 amino acids’
proteins [7-11]. Normal cells all have MGMT expres-
sion, while some malignant tumors will lose MGMT ex-
pression which will induce the damage of DNA repair
and the carcinogenesis of cells [7-11,38,39]. ERCC1 is a
member of the exonuclease repair enzyme family and its
low expression is always related to elevated cancer inci-
dence, while its high expression is always related to re-
sistance to platinum drugs [12-16]. Recent studies have
confirmed that ERCC1 is the key enzyme of the DNA re-
pair induced by cisplatin and it has been shown that
ERCC1 expression of some malignant tumors played an
important role in guiding chemotherapy [17-21,37]. The
hMSH2 gene is located in 2P
16 and is the first separated
MMR. It can repair DNA mismatch and retain the inte-
grality and stability of genes. Many recent papers have
reported that the loss of hMSH2 protein expression was
crucial to the genesis and progression of malignant tu-
mors [7-11,40-42]. hMLH1 is also a type of MMR which
can also inhibit carcinogenesis by repairing DNA mis-
matching. Mutation of the hMLH1 gene will induce the
genesis of many malignant tumors [7-11,41].Conclusions
Our data have shown that the positive rates of MGMT,
ERCC1, hMSH2, and hMLH1 were significantly lower
in pancreatic ductal adenocarcinoma than in non-
cancerous pancreatic tissues of rats, and the ductal epi-
thelia of non-cancerous pancreas which had negative
expression of MGMT, ERCC1, hMSH2, and hMLH1 all
shown atypical-hyperplasia. The results show that there
was loss expression of MGMT, ERCC1, hMSH2, and
hMLH1 in the course of genesis of pancreatic cancer in-
duced by DMBA in rats, which might be the mechanism
of carcinogenesis by DMBA. Therefore, testing the ex-
pression of MGMT, ERCC1, hMSH2, and hMLH1 in
pancreatic cancer might play an important role in guid-
ing the treatment of human pancreatic cancer.
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